Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.

Today, Benzinga's options scanner spotted 9 options trades for AstraZeneca. This isn't normal. The overall sentiment of these ...

Goldman Sachs updated its price target on AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN) shares to GBP150.67, down from GBP155.58, while reaffirming a Buy rating on the stock. The adjustment follows a ...

Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on AstraZeneca (AZN – Research Report), with a ...

While the stock market remains concerned about US President Donald Trump's trade policy, it has been less impactful than ...

A fresh earnings release was the news development powering AstraZeneca's (NASDAQ: AZN) share price higher on Thursday.

AstraZeneca's strong results boosted the FTSE 100 to a record close, aided by the Bank of England's rate cut. The BoE's ...

How does the US stock market stack up against its UK counterpart and how does their recent performance compare?

Strong results from AstraZeneca helped London's blue-chip index notch a record close on Thursday, while a dovish majority ...

AstraZeneca on Thursday warned that it could be fined millions of dollars in importation tax fines as Chinese authorities ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...